Drug clinical trials on high-grade gliomas: challenges and hopes

作     者：Mengqian Huang Shenglan Li Parker Li Zhuang Kang Botao Zhang Wenbin Li Mengqian Huang;Shenglan Li;Parker Li;Zhuang Kang;Botao Zhang;Wenbin Li

作者机构：Cancer CenterBeijing Tiantan HospitalCapital Medical UniversityBeijing 100070China Clinical MedicineShanghai Jiao Tong University School of MedicineShanghai 200025China 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2023年第20卷第12期

页      面：947-954页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1006[医学-中西医结合] 100706[医学-药理学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 100602[医学-中西医结合临床] 

基　　金：financially supported by the Talent Introduction Foundation of Tiantan Hospital (Grant No.RCYJ-2020-2025-LWB) Clinical Major Specialty Projects of Beijing (Grant No.2-1-2-038) 

主　　题：glioma chemotherapy pathology 

摘      要：Gliomas are the most common group of malignant central nervous system tumors across all ages and have high *** to histopathologic criteria and molecular pathology,gliomas are classified as grades 1–***-grade gliomas(HGG),including the most aggressive subtype,glioblastoma(GBM),belong to grade 3 or *** a standard therapy comprising surgical resection,chemotherapy,and radiation is available,almost all patients with HGG experience recurrence within several months and a dismal prognosis1.